Daclizumab, a humanized monoclonal antibody, has a complex history in the pharmaceutical landscape. Primarily recognized for its role in preventing organ rejection and its subsequent exploration in treating relapsing multiple sclerosis (MS), this biological agent targets the CD25 antigen, a key component of the interleukin-2 receptor. For researchers and B2B buyers seeking advanced biochemicals, understanding Daclizumab's properties, applications, and market status is crucial.

The primary function of Daclizumab lies in its ability to bind to CD25, effectively blocking the interaction between interleukin-2 (IL-2) and its high-affinity receptor. This mechanism is vital for modulating T-cell activity, a cornerstone in managing overactive immune responses. In clinical practice, this translated into preventing acute graft-versus-host disease in organ transplantation and was later investigated for its potential in treating the autoimmune nature of multiple sclerosis. Many pharmaceutical companies specializing in antibody production, particularly those acting as reliable suppliers in China, offer Daclizumab for research purposes.

However, the therapeutic journey of Daclizumab was marked by significant safety concerns. Reports of serious adverse events, including inflammatory brain disorders such as encephalitis and meningoencephalitis, alongside instances of liver damage, led to its voluntary withdrawal from the global market. This critical safety profile underscores the challenges in developing targeted biologics and emphasizes the importance of rigorous safety evaluations by any manufacturer or supplier. For procurement managers and R&D scientists, this historical context is essential when considering the purchase of such compounds.

Despite its discontinuation as a therapeutic drug, Daclizumab remains a valuable tool in the scientific community. Its specific targeting of CD25 makes it an indispensable reagent for in-depth immunological research. Scientists often buy Daclizumab to investigate T-cell proliferation, immune tolerance, and the pathogenesis of various autoimmune and inflammatory conditions. The availability of high-purity Daclizumab from reputable chemical suppliers facilitates these critical studies, allowing researchers to explore its biological effects without the complexities of clinical application.

For those looking to procure Daclizumab, understanding the supply chain is key. Companies that manufacture and supply such specialized biochemicals often provide detailed documentation, including Certificates of Analysis (CoA) and Safety Data Sheets (SDS), ensuring product quality and safety for research use. When considering a purchase, inquiring about the product's origin, purity, and the manufacturer's credentials is a standard practice for B2B procurement. For instance, sourcing from established suppliers in China can offer competitive pricing for research-grade Daclizumab.

In conclusion, while Daclizumab is no longer prescribed clinically, its scientific legacy continues. Its unique mechanism of action and the lessons learned from its safety profile make it a relevant compound for ongoing research in immunology, pharmacology, and the development of future immunotherapies. Any procurement decision should be informed by its research utility and the quality assurance provided by its suppliers.